JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

133.13

-0.58%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

133 / 352 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. jaan 2026, 22:31 UTC

Tulu

KLA Posts Higher 2Q Profit On Product and Services Sales Growth

29. jaan 2026, 22:05 UTC

Tulu

Stryker Logs Higher 4Q Profit On Sales Gains

29. jaan 2026, 21:54 UTC

Tulu

Visa 1Q Sales Climb on Strong Holiday Shopping -- Update

29. jaan 2026, 21:36 UTC

Tulu

Visa 1Q Sales Climb on Strong Holiday Shopping

29. jaan 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China: to Hold 67% of Joint Venture With Rio Tinto

29. jaan 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China: Deal Valued at Roughly BRL4.69 Billion

29. jaan 2026, 23:53 UTC

Omandamised, ülevõtmised, äriostud

Aluminum Corp. of China Says It, Rio Tinto Propose to Buy 69% Stake in Companhia Brasileira de Aluminio S.A.

29. jaan 2026, 23:51 UTC

Tulu

Correction to Intel Earnings Article on Jan. 22 -- WSJ

29. jaan 2026, 23:49 UTC

Market Talk

Nikkei May Decline After Wall Street Tech Selloffs -- Market Talk

29. jaan 2026, 23:49 UTC

Market Talk

Gold Rises Amid Ongoing Iran Tensions -- Market Talk

29. jaan 2026, 23:47 UTC

Market Talk

Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk

29. jaan 2026, 23:35 UTC

Tulu

Apple Posts Blowout iPhone Sales on Surging China Demand -- 2nd Update

29. jaan 2026, 23:32 UTC

Market Talk

REA's 1H Result Could Jolt Share Price More Than Usual -- Market Talk

29. jaan 2026, 23:32 UTC

Market Talk

Global Equities Roundup: Market Talk

29. jaan 2026, 23:15 UTC

Market Talk

Tulu

Visa Says High Earners Still Lead Spending Growth -- Market Talk

29. jaan 2026, 22:27 UTC

Tulu

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

29. jaan 2026, 22:27 UTC

Tulu

GE Vernova Gains After Earnings. Guidance Boost Was Enough to Lift the Stock. -- Barrons.com

29. jaan 2026, 22:12 UTC

Tulu

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

29. jaan 2026, 21:55 UTC

Tulu

Micron Stock Rises. Samsung Signals a 'Golden Era' for Memory Chips. -- Barrons.com

29. jaan 2026, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

29. jaan 2026, 21:50 UTC

Tulu

These Stocks Are Today's Movers: Microsoft, Meta, Tesla, Joby Aviation, SAP, Royal Caribbean, and More -- Barrons.com

29. jaan 2026, 21:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

29. jaan 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

29. jaan 2026, 21:49 UTC

Tulu

Honeywell Delivers Solid Earnings Ahead of Its Corporate Breakup -- Barrons.com

29. jaan 2026, 21:46 UTC

Tulu

Apple Posts Blowout iPhone Sales on Surging China Demand -- Update

29. jaan 2026, 21:36 UTC

Tulu

Lockheed Martin Stock Jumps on Guidance and Government Missile Deal -- Barrons.com

29. jaan 2026, 21:32 UTC

Tulu

Visa Beats Expectations on Stronger Spending. The Stock Is Falling. -- Barrons.com

29. jaan 2026, 21:32 UTC

Tulu

Sandisk Beats Earnings. The Stock Is Soaring. -- Barrons.com

29. jaan 2026, 21:30 UTC

Tulu

Apple Posts Blowout IPhone Sales on Surging China Demand -- WSJ

29. jaan 2026, 21:30 UTC

Tulu

Apple 1Q Mac Rev $8.39B >AAPL

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

133 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.